[Biomarkers in testicular cancer.]

Area of Science:

• Oncology
• Biomarker Research
• Molecular Diagnostics

Background:

• Testicular cancer diagnosis and management rely on accurate biomarkers.
• Current biomarkers have limitations in sensitivity and specificity.
• The need for improved diagnostic and prognostic tools is critical.

Purpose of the Study:

• To review the current landscape of biomarkers for testicular cancer.
• To assess biomarkers in diagnosis, prognosis, treatment response, and relapse.
• To evaluate the clinical utility of established and emerging biomarkers.

Main Methods:

• A non-systematic review of clinical guidelines and recent literature.
• Focus on biomarkers relevant to testicular germinal tumors.
• Analysis of established and novel molecular markers.

Main Results:

• Alphafetoprotein (AFP), beta human chorionic gonadotropin (β-HCG), and lactate dehydrogenase (LDH) are commonly used.
• Elevated AFP, β-HCG, and LDH can aid in diagnosis but lack sufficient sensitivity.
• Micro-RNAs show specific elevation in testicular germinal tumors, but clinical benefit and standardization are under investigation.

Conclusions:

• Established biomarkers (AFP, β-HCG, LDH) are useful for confirming diagnosis when elevated.
• These classic biomarkers have limited sensitivity for sole diagnostic reliance.
• Micro-RNAs present promising results for testicular cancer but are not yet ready for routine clinical application.